Is your small business on the brink of taking its innovative cancer research to the next level, but needs early-stage technology financing? If so, we encourage you to apply for new contract funding opportunities available from the National Cancer Institute’s (NCI) Small Business Innovation Research (SBIR) Program by November 7, 2011.
The NCI SBIR Program has launched 12 new funding opportunities that meet the scientific priorities of the NCI and are ripe for commercial investment and integration. The solicitation is intended to help finance and lead innovations in cancer prevention, detection, diagnosis, treatment, and basic research. Contract funding opportunities are only available once a year, so apply early!
This year, the NCI SBIR Program has released $8 million for 12 new contract funding opportunities in a range of novel technology areas. Compared to grant funding opportunities, SBIR contract topics are more focused and require the completion of specific activities and deliverables. The current NCI FY2012 solicitation provides funding opportunities to small businesses to support the research, development, and ultimately commercialization of many areas of priority to the NCI including, but not limited to:
In Vitro and Companion Diagnostics
Nanotechnology-based Sensors and Therapeutics
Imaging Technology and Agents
Among the 12 new funding opportunities, the NCI SBIR Program has announced three NIH Technology Transfer (TT) Inventions released as contract topics. The goal of each SBIR-TT topic is to identify a small business which can obtain both SBIR funding and licenses to the technology to perform the necessary R&D to advance the technology towards commercialization.
The FY2012 technology transfer contract topics are:
310 Simplified Tumor Microarray Instrument for Clinical and Research Settings
311 High Throughput Isolation of Antigen Specific T-cells for Cancer Therapy
075 A Low Molecular Weight Thyroid-Stimulating Hormone Receptor Agonist for Thyroid Cancer – Funding will be provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), while the receipt, review, and contracting will be handled by NCI.
On October 7, 2011, the NIH and NCI Development Center will host a pre-proposal public meeting and webinar for these three topics. The meeting will provide technical background and details on the process for licensing these technologies from NIH. The presentations will be followed by an interactive Q&A session with the audience. Stay tuned for more information on this upcoming event!
Learn more about NCI’s SBIR Programs and these contract funding opportunities.
NCI SBIR Program Participation:
• To participate, the small business concern (SBC) must be an organized for-profit U.S. business of 500 employees or fewer, including affiliates
• The SBC must:
• Be at least 51 percent U.S. owned by individuals and independently operated
• Be at least 51 percent owned and controlled by a for-profit business concern that is at least 51 percent owned and controlled by one or more individuals
• Have a Principal Investigator whose primary employment must be with the small business concern at the time of award and for the duration of the project period
• SBIR & STTR awards provide recognition, verification, and visibility
• SBIR & STTR funding can be a leveraging tool to attract additional funding from other third-party investors
• Awards are not loans; no repayment is required
SBIR & STTR funding is non-dilutive capital (i.e., an award does not impact the company’s stock or shares in any way). Intellectual property rights to technologies developed under these programs are retained by the small business concern.
The SBIR & STTR Programs are NCI’s engine of innovation for developing and commercializing novel technologies and products to prevent, diagnose, and treat cancer. The SBIR & STTR Programs are government set-aside programs for domestic small businesses to engage in research and development that has the potential for commercialization and public benefit.